GW/Almirall wangle higher German Sativex price
This article was originally published in Scrip
Executive Summary
Almirall has managed to renegotiate in Germany a new and "acceptable" reimbursement price for its/GW Pharmaceuticals' plant-derived cannabinoid for spasticity in multiple sclerosis, after months of uncertainty selling the drug at an "uneconomic price".